Proteomics International (ASX: PIQ) Breaks New Ground with Kidney Disease Prediction in Type 1 Diabetes

Key Highlights:

• Proteomics International (ASX: PIQ) has unveiled a groundbreaking study showing that its PromarkerD test can accurately predict chronic kidney disease (CKD) in type 1 diabetes patients.
• The study achieved a remarkable area under the curve (AUC) of 0.93, signaling a major advancement in diabetic kidney disease management.
• Previously validated for type 2 diabetes, PromarkerD’s new application in type 1 diabetes opens up significant market opportunities.
• This breakthrough addresses a critical health need, with type 1 diabetes affecting over 10% of the global diabetic population.

Proteomics International Laboratories Ltd (ASX: PIQ) has just announced a game-changing development in the fight against chronic kidney disease (CKD) in type 1 diabetes patients. The company’s PromarkerD test, already celebrated for its success in predicting CKD in type 2 diabetes, has now demonstrated its effectiveness in the more challenging type 1 diabetes arena. This expansion marks a significant milestone, not just for Proteomics International, but for millions of patients worldwide.

Presented at the Australasian Diabetes Conference 2024, the study revealed that PromarkerD could predict renal decline in type 1 diabetes with an impressive AUC of 0.93. This high level of accuracy is a strong testament to the test’s capability, offering a new level of early detection that could transform how clinicians manage diabetic kidney disease. The earlier the detection, the better the chances of intervening before severe complications arise.

Type 1 diabetes, which makes up around 10% of all diabetes cases globally, poses unique challenges in managing complications like CKD. PromarkerD’s ability to forecast kidney function decline in this group is nothing short of revolutionary, providing doctors with a powerful new tool to improve patient outcomes.

Dr. Richard Lipscombe, Managing Director of Proteomics International, couldn’t be more excited about the implications of this discovery. "PromarkerD’s versatility in accurately predicting kidney disease across different types of diabetes is a huge leap forward. This breakthrough opens up new possibilities for protecting kidney health in a broader patient population," he said.

Professor Tim Davis, a prominent endocrinologist and lead author of the study, echoed this enthusiasm. “The ability of PromarkerD to detect early signs of kidney decline in type 1 diabetes patients is particularly beneficial. Early identification allows for timely intervention, which could significantly improve outcomes for these patients,” Davis remarked.

This advancement is especially critical as diabetes remains the leading cause of end-stage renal disease worldwide. The expansion of PromarkerD’s application to type 1 diabetes puts Proteomics International at the cutting edge of predictive diagnostics, addressing a major and growing healthcare challenge.

On the back of today’s ASX announcement, Proteomics International (ASX: PIQ) shares surged 6.59%, reaching A$0.89 at 1:46 PM AEST, August 23, 2024.